Navigation Links
Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
Date:4/18/2011

NEW YORK, April 18, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced today that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd. (Torii), JT's pharmaceutical business subsidiary, has commenced the Phase 3 clinical program of ferric citrate in Japan for the treatment of patients with hyperphosphatemia.  Under the license agreement with JT/Torii, within 30 days, Keryx will receive a non-refundable milestone payment of $5 million from JT/Torii for the achievement of this milestone.  Zerenex™ (ferric citrate), a ferric iron-based phosphate binder, is also in Phase 3 clinical development in the United States for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis.

Ron Bentsur, Chief Executive Officer of Keryx, stated, "We congratulate our partner, JT/Torii, on the initiation of the Phase 3 program in Japan and are excited by their progress.  We believe that this serves to further validate the commercial potential for Zerenex worldwide."  

Keryx holds a worldwide license (except for certain Asian Pacific countries) to Zerenex from Panion & BF Biotech, Inc.

Sublicense Agreement with Japan Tobacco & Torii PharmaceuticalIn September 2007, Keryx sublicensed to JT and Torii the exclusive rights for the development and commercialization of its hyperphosphatemia drug, Zerenex (ferric citrate), in Japan. The licensing arrangement calls for JT and Torii to pay to Keryx up to $100 million in up-front license fees and payments upon the achievement of specified milestones, of which $28 million has been received by Keryx to date.  In addition, upon commercialization, JT and Torii will make royalty payments to Keryx on net sales of the drug in Japan. JT and Torii are responsible for all development and commercializat
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
4. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
5. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
7. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
8. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
9. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
10. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
11. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
(Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
(Date:7/31/2014)... 31, 2014  Decision Resources Group,s experts ... by the Affordable Care Act (ACA), which ... pharmaceutical therapies. The ACA altered how Managed ... regulations and expanded access via government-supported programs. ... exchanges—state-based marketplaces set up by states or ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
... Untold Numbers of Consumers Still Left Disabled By Its ... GlaxoSmithKline, the maker of popular denture adhesives Poligrip and Super ... its denture adhesive products.  The pharmaceutical giant has added the potentially ... consuming large quantities of zinc over an extended period of time ...
... , , SHANGHAI , ... WX ), a leading pharmaceutical, biotechnology and medical device R&D outsourcing ... announced that it will release financial results for the fourth quarter of ... 8, 2010 (which will be Tuesday morning, March 9, 2010 ...
Cached Medicine Technology:Leading Denture Cream Litigation Firm Welcomes GSK Announcement of Removal of Zinc From Its Denture Creams 2Leading Denture Cream Litigation Firm Welcomes GSK Announcement of Removal of Zinc From Its Denture Creams 3WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release 2WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release 3
(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly experienced ... of power morcellators in gynecological surgeries, Bernstein Liebhard LLP ... to withdraw a number of power morcellators marketed by ... a report from The New York Times, some critics ...
(Date:8/1/2014)... Chicago, Illinois (PRWEB) August 01, 2014 ... filed across the country, Ronald E. Johnson, Jr. has ... injured by AndroGel and other testosterone medications. Since the ... & Johnson, P.S.C. have worked diligently to investigate and ... strokes, pulmonary embolisms, and blood clots as a result ...
(Date:8/1/2014)... Washington, DC (PRWEB) August 01, 2014 ... Mike Thompson (D-CA), Gregg Harper (R-MS), and Peter ... H.R. 5380, the Medicare Telehealth Parity Act of ... "We fully support this effort to improve healthcare ... Linkous, chief executive officer of ATA. "These cost-saving ...
(Date:8/1/2014)... PA (PRWEB) August 01, 2014 Hot off ... the destination spa category of the World’s Best Awards ... off a month-long celebration of National Relaxation Day (technically August ... a series of MAJOR experts to help guests celebrate relaxation ... important it is for health and wellness to carve out ...
(Date:8/1/2014)... Patients with the progressive, deadly respiratory ailment known as ... to battle the disease, the U.S. Food and Drug ... new treatment, an inhaled spray called Striverdi Respimat (olodaterol) ... which is often linked to smoking, involves multiple lung ... Patients with COPD may experience a number of symptoms, ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:FDA Approves New Treatment for People With COPD 2
... patient communities call on national policymakers in Latin America to ... people with atrial fibrillation (AF) each year, AF increases the ... five of all ischemic strokes caused by a blood clot ... of people in Latin America suffer from AF , ...
... Parker, Ph.D., assistant professor of research in the Department of ... $418,000 from the National Institute of Neurological Disorders and Stroke ... particular gene might be involved in the progression of spinal ... children younger than 2 years old. "Although most ...
... Transplantation specialists have proposed changes to the allocation and ... policy modifications take into account the scarcity of available ... to those most in need in order to reduce ... are available in the September issue of Liver ...
... Reporter , FRIDAY, Sept. 9 (HealthDay News) -- Experts ... to meet Friday to discuss problems linked to long-term ... and Reclast. These drugs, known as bisphosphonates, ... But researchers have linked long-term use with a small ...
... at the University of Maryland Medical Center have transplanted ... an experimental repair process before transplantation. The procedure is ... evaluate the efficacy of repairing, before transplant, lungs that ... organ donation. The results of this study, if successful, ...
... diagnosed each year with stage III or,locally ... not a viable,treatment option. Optimizing nonsurgical treatment ... endeavor. In an article published online,September 8, ... Cancer Institute, RTOG,researchers report that treating patients ...
Cached Medicine News:Health News:Medical and patient communities call for urgent action to prevent stroke crisis in Latin America 2Health News:Medical and patient communities call for urgent action to prevent stroke crisis in Latin America 3Health News:Medical and patient communities call for urgent action to prevent stroke crisis in Latin America 4Health News:Wayne State University researcher to study spinal muscular atrophy 2Health News:Changes to distribution of livers for transplant proposed 2Health News:Changes to distribution of livers for transplant proposed 3Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 2Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 3Health News:First US patient receives specially processed donor lungs at the University of Maryland 2Health News:Concurrent chemo and radiation therepy improves long-term survival for inoperable stage III lung cancer 2
... SG-2002 Stand-Alone Ganzfeld produces ... stimuli, which will elicit ... be amplified and recorded. ... is painted with a ...
... crescent-shaped interbody spacer used to provide anterior ... is available in either titanium or PEEK-OPTIMA, ... TraXis is implanted through a posterolateral approach ... and then curved across the midline to ...
... LKCs Sweep VEP technology is designed for productivity ... in conjunction with doctors from the University of ... over a decade on over 5,000 subjects. All ... be set and stored, or can be preset ...
... ALL-NEW CV-3000 Computerized Vision Tester offers ... and expands the many features of ... demand for delegating the refraction, electronic ... to generate an incredible interest in ...
Medicine Products: